Welcome!

News Feed Item

Bladder Cancer: So Much Cost, Such Little Progress

LONDON, March 20, 2014 /PRNewswire/ --



The alarming truth about the huge financial and personal impact of bladder cancer is highlighted in a new paper published in European  Urology[1]. The UK charity, Action on Bladder Cancer, co-authors an editorial[2] on the paper, drawing attention to the urgent need to address the enormous, yet largely ignored, burden that this distressing disease places on individuals and society.

     (Logo: http://photos.prnewswire.com/prnh/20130507/613105 )

Bladder cancer has the highest lifetime treatment costs per patient of all cancers[3]. The direct medical costs of cancer care in the UK are £65M[4]. As the seventh most common cancer in the UK, bladder cancer accounts for 1 in 30 new cases of cancer each year[5]. Even so, outcomes for bladder cancer have changed little for three decades, despite significant improvements in the 5-year survival rates for prostate and kidney cancers during this same period[2].

Bladder cancer has a deep and devastating reach into the health of our society. Overall, deaths from the disease remain higher in England than other European countries with similar incidence rates and survival is worsening[6].  On average 14 people die each day from bladder cancer[4], and yet it is largely neglected by those who could make a difference to the lives of so many people.

The paper and editorial discuss the key issues which are creating and sustaining this unacceptable situation:

  • There are large gaps in our knowledge regarding the efficacy and cost-effectiveness of treatment approaches
  • There is a lack of research funding compared to other cancers; despite being the seventh most common cancer, bladder cancer receives just 0.6% of NCRI cancer research spending in the UK[7]
  • There is a lack of sufficient randomized controlled trials (RCTs). RCTs provide the strongest evidence on which clinicians can base their practice however only 238 RCTs were published for bladder cancer between 1995 and 2010[8].
  • There is a clear and urgent need for the development of new drugs for bladder cancer.

As a result, bladder cancer still does not have a robust evidence base to support much of what is current everyday practice. Patient pathways of care are complex and prolonged, resulting in large variations in practice worldwide. Even at the basic level of public awareness of the disease, many people have not heard of bladder cancer and do not recognise that even just one episode of visible blood in the urine may indicate that bladder cancer may be present. For many people, diagnosis is delayed or misdiagnosed resulting in worse clinical outcomes. This is clearly just not good enough.

Mr Richard T Bryan, Chief Investigator, Bladder Cancer Prognosis Programme, and Senior Research Fellow, University of Birmingham, and Action on Bladder Cancer Regional Advisor says "The review by Svatek et al demonstrates the huge costs associated with the diagnosis and management of bladder cancer, the large variations in practice worldwide, and the significant gaps in our knowledge. Our accompanying editorial expands on these themes and others; most importantly, the lack of improvement in outcomes for bladder cancer patients over the last three decades, the poor funding for bladder cancer research, and the poor awareness of bladder cancer amongst the general public and the non-urologic scientific community. We need to advance the cause for bladder cancer patients and make much more progress with this very common disease."

Bladder cancer lags starkly behind nearly all other cancers. Action needs to be taken now to improve the life expectancy of so many people with bladder cancer. Quite simply, more has to be done.

About  Action  on  Bladder  Cancer 

Action on Bladder Cancer is a UK charity working to improve public awareness, medical knowledge and the priority of bladder cancer on the UK health agenda, to ensure earlier recognition and diagnosis and so allow more effective management to improve the outcomes for people with bladder cancer. (http://www.actiononbladdercancer.org).

References:

  1. Svatek et al. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology. Published online Feb 2014. Abstract available at: http://www.europeanurology.com/article/S0302-2838(14)00018-9/abstract/the-economics-of-bladder-cancer-costs-and-considerations-of-caring-for-this-disease
  2. Bryan RT et al. So much cost, such little progress. European Urology. Published online Feb 2014.  http://www.europeanurology.com/article/S0302-2838(14)00160-2/abstract
  3. Sievert KD et al. Economic aspects of bladder cancer. What are the benefits and costs? World  J  Urol. Jun 2009; 27(3): 295-300.
  4. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14:1-iv
  5. Cancer Research UK, Cancer Stats Key Facts, Bladder Cancer http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/bladder-cancer/uk-bladder-cancer-statistics
  6. Eylert MF et al (2014). Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. Journal  of  Clinical  Urology 0(0) 1-9
  7. National Cancer Research Institute. NCRI spend by cancer site.  Available at http://www.ncri.org.uk/what-we-do/research-database
  8. Bachir, B. G., Shariat, S. F., Zlotta, A., Svatek, R., Black, P. C., Shah, J. B., Kassouf, W., Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada) (2013), Demographic analysis of randomized controlled trials in bladder cancer.  BJU  International, 111: 419-426


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assis...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
SYS-CON Events announced today that Carbonite will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Carbonite protects your entire IT footprint with the right level of protection for each workload, ensuring lower costs and dependable solutions with DoubleTake and Evault.
In his session at 20th Cloud Expo, Brad Winett, Senior Technologist for DDN Storage, will present several current, end-user environments that are using object storage at scale for cloud deployments including private cloud and cloud providers. Details on the top considerations of features and functions for selecting object storage will be included. Brad will also touch on recent developments in tiering technologies that deliver single solution and an end-user view of data across files and objects...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which i...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developer...